Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma.

Yang Y, Luo M, Zhang K, Zhang J, Gao T, Connell DO, Yao F, Mu C, Cai B, Shang Y, Chen W. · 2020

Read Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. by Yang Y, Luo M, Zhang K, Zhang J, Gao T, Connell DO, Yao F, Mu C, Cai B, Shang Y, Chen W. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6978386.txt.

Introduction

Yang and co-authors uncover a feedback loop that lets melanoma resist an iron-based death drug. Their study appeared in Nature Communications. Ferroptosis is a form of cell death driven by iron and damaged fats. The drug erastin triggers it by binding channel proteins VDAC2 and VDAC3 on mitochondria.

Cells fight back. Erastin treatment switches on a protein called Nedd4, driven by the factor FOXM1. Nedd4 tags the channels for destruction, lowering their levels and blunting the drug. Removing Nedd4 kept channels intact and made cancer cells far more sensitive to erastin. Boosting the channels had the same effect in tumours grown in mice. The loop, the authors say, frames a first plan for defeating resistance to ferroptosis drugs.

Catalog record

CREATORYang Y, Luo M, Zhang K, Zhang J, Gao T, Connell DO, Yao F, Mu C, Cai B, Shang Y, Chen W.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6978386

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma By Yongfei Yang, Meiying Luo, Kexin Zhang, Jun Zhang, Tongtong Gao, Douglas O’ Connell, Fengping Yao, Changwen Mu, Bingyu Cai, Yuxue Shang, Wei Chen Published in: Nature Communications DOI: 10.1038/s41467-020-14324-x ABSTRACT Ferroptosis is a newly defined form of regulated cell death characterized by the iron-dependent accumulation of lipid hydroperoxides. Erastin, the ferroptosis activator, binds to voltage-dependent anion channels VDAC2 and VDCA3, but treatment with erastin can result in the degradation of the channels. Here, the authors show that Nedd4 is induced following erastin treatment, which leads to the ubiquitination and subsequent degradation of the channels. Depletion of Nedd4 limits the protein degradation of VDAC2/3, which increases the sensitivity of cancer cells to erastin. By understanding the molecular mechanism of erastin-induced cellular resistance, we can discover how cells adapt to new molecules to maintain homeostasis. Furthermore, erastin-induced resistance mediated by FOXM1-Nedd4-VDAC2/3 negative feedback loop provides an initial framework for creating avenues to overcome the drug resistance of ferroptosis activators. INTRODUCTION Cell death is critical in diverse aspects of mammalian development, homeostasis, and disease. In recent years, several distinct forms of programmed cell death (PCD) have been identified with each having unique cellular mechanisms. Ferroptosis is a newly recognized form of PCD, which is readily distinguishable from other types of PCD such as apoptosis, necroptosis, and autophagic cell death at morphological, biochemical, and genetic levels1,2. Recent studies have demonstrated that not only the primary cells but also drug-resistant cells from different cancers are especially sensitive to ferroptosis3–8. Moreover, most notably in malignant melanoma, where both receptor tyrosine kinase-mediated resistance to mitogen-activated protein kinase targeted therapies and activation of the inflammatory signaling associated with immune therapy lead to increased sensitivity to ferroptosis5. These works overcome reactionary resistance by developing strategies to destroy cancer cells by inducing ferroptotic cell death. The voltage-dependent anion channel (VDAC) is a pore located at the outer membrane of the mitochondrion. It allows the entry and exit of numerous ions and metabolites between the cytosol and the mitochondrion. By managing the exchange of molecules between cellular compartments, VDAC regulates various cellular processes like apoptosis, metabolism, ion homeostasis, and thus, impacts many diseases including cancer9. Erastin, the first identified ferroptosis activator in 2003, was found to exhibit substantial lethality in human tumor cells harboring mutations in oncogenes HRAS, KRAS, and BRAF10. It has been reported that erastin induces ferroptosis through directly binding to VDAC2/3 to alter the permeability of the outer mitochondrial membrane, which decreases the rate of NADH oxidation10. Besides exerting targeted effects, erastin also enhances chemotherapy, targeted therapy, and immunotherapy in certain cancer cells5,11,12, suggesting a potential role of erastin in cancer cell treatment. However, after 10 h of erastin treatment, both VDAC2 and VDAC3 were no longer detectable, and this low expression level of VDAC2/3 led to erastin resistance10. The mechanism by which erastin induces specific downregulation of VDAC2/3 has not been fully elucidated. Neuronal precursor cell-expressed developmentally downregulated 4 (Nedd4) is an essential member of HECT domain E3 ligase family in eukaryotes and remains conservative during the evolution. It is comprised of a catalytic C-terminal HECT domain, an N-terminal calcium/lipid-binding domain (C2 domain), and four WW domains responsible for cellular localization and substrate recognition13. Nedd4 plays a pivotal role in numerous biological processes through proteasomal degradation of its substrates that generally have a PPxY motif for WW domain recognition, and are found in the nucleus or at the plasma membrane13. Here, we report that erastin activates the transcriptional expression of Nedd4 through FOXM1 in melanoma cells. As an E3 ligase, Nedd4 binds to the PPxY motifs of VDAC2/3 through its WW domain and degrades them. Downregulation of Nedd4 by shRNA rescued erastin-induced protein elimination of VDAC2/3 and increased the sensitivity of melanoma cells to erastin. Together, we identify an E3 ligase that regulates ferroptosis in melanoma cells and provide further insight into Nedd4 as a target for overcoming erastin-induced resistance to cancer therapy. RESULTS Erastin degrades VDAC2/3 in melanoma cells To test whether erastin can degrade VDAC2/3 in melanoma cells, we transfected A375 melanoma cells bearing the BRAFV600E mutation with GFP-VDAC2 or GFP-VDAC3 and mCherry-VDAC1. Upon erastin treatment, the fluorescence intensity levels of VDAC2 and VDAC3 were sharply reduced, but the level of VDAC1 was only slightly reduced (Fig. 1a). Immunoblotting of endogenous VDAC1, VDAC2, and VDAC3 with their specific antibodies (Supplementary Fig. 1a) showed similar results in erastin treated A375 and G-361 cells, both of which carry BRAFV600E mutation (Fig. 1b and Supplementary Fig. 1b). We further examined whether knockdown of VDAC2/3 suppresses erastin-induced ferroptosis in melanoma cells. As shown in Fig. 1c, d, depletion of VDAC2 or VDAC3 by RNAi resulted in significantly increased resistance to erastin compared to control RNAi. Indeed, suppression of VDAC2 or VDAC3 significantly inhibited erastin-induced ferroptotic events, including lipid ROS production, iron accumulation, glutathione (GSH) depletion, and glutathione disulfide (GSSG) generation (Fig. 1c, d). Moreover, combined interference with VDAC2 and VDAC3 showed a stronger effect on lipid ROS production and iron accumulation (Fig. 1c, d). Overexpression of VDAC2 or VDAC3 individually did not affect erastin-induced ferroptotic cell death, but VDAC2 and VDAC3 together facilitated erastin-induced ferroptosis in A375 cells (Fig. 1e, f). Together, these results indicate that both VDAC2 and VDAC3 are essential for erastin-induced ferroptosis in A375 cells, and these results are consistent with previous work in engineered human tumor cells (BJTERT/LT/ST/RASV12)10.Fig. 1Erastin treatment promotes ubiquitin–proteasomal degradation of VDAC2/3.a A375 cells expressing GFP-VDAC2 or GFP-VDAC3 and mCherry-VDAC1 were treated with erastin (5 µM). Representative images were taken at the indicated time after treatment. Scale bars, 10 μm. Fluorescence intensity was assayed using Image J software. b A375 cells were treated with erastin at the indicated time (0–12 h, 10 µM) or indicated concentrations (0–10 µM, 12 h). Western blot analysis shows the expression of VDAC2, VDAC3, and VDAC1 in indicated cells. c, d Knockdown of VDAC2 and VDAC3 individually or in combination suppressed erastin-induced ferroptotic cell death. Indicated cells were treated with erastin (5 µM) for 24 h. Cell viability was assayed using a CCK8 kit. The lipid formation was measured by MDA assay. The accumulation of Fe2+ was measured by iron detection assay. The concentrations of GSH and GSSG were detected by relative assay kits (c). The protein level of VDAC2/3 was assessed by immunoblotting (d). e, f Overexpression of VDAC2 and VDAC3 together increased erastin-induced ferroptotic cell death. Indicated cells were treated with erastin (5 µM) for 24 h. Cell viability, intracellular MDA, Fe2+, GSH, and GSSG levels were measured (e). The overexpression of VDAC2/3 was assessed by immunoblotting (f). g A375 cells were treated with erastin (5 µM) for 8 h, then MG132 (50 mM) or NH4Cl (50 mM) were added into the culture medium for 4 h. The protein level of VDAC2/3 was analyzed by western blot. h A375 cells were transfected with indicated DNA constructs. After 48 h transfection, cells were treated with DMSO or erastin (5 µM) for 8 h, then MG132 (50 mM) was added into the culture medium for 4 h. Lysates from A375 cells were immunoprecipitated with mouse anti-Myc. Western blots were performed to analyze the presence of indicated proteins and levels of ubiquitination. Actin was used as a loading

Read the complete text